Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia.

Article Details

Citation

Wiersma HE, Wiegman A, Koopmans RP, Bakker HD, Kastelein JJ, van Boxtel CJ

Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia.

Clin Drug Investig. 2004;24(2):113-20. doi: 10.2165/00044011-200424020-00006.

PubMed ID
17516697 [ View in PubMed
]
Abstract

OBJECTIVE: To determine pharmacokinetic data for pravastatin in children, since current data are insufficient in this age group. SUBJECTS AND METHODS: A 2-week, multiple-dose, steady-state pharmacokinetic study was carried out with pravastatin 20mg daily in 24 children with familial hypercholesterolaemia (aged 8-16 years; 12 prepubertal, 12 pubertal). A plasma concentration-time curve was performed on day 14. Pharmacokinetic curves for each individual were constructed using nonparametric methods, yielding area under the plasma concentration-time curve (AUC), maximum plasma concentration (C(max)) and half-life (t((1/2))). Clearance values and volumes of distribution were calculated from these parameters. Cholesterol lowering was observed on day 14 and 6 weeks after the start of pravastatin. RESULTS: The C(max) in prepubertal (group A) children (52.1 +/- 27.0 mug/L [mean +/- SD]) differed, although not significantly (p = 0.09, unpaired two-tailed t-test), from the C(max) in adolescents (group B) [31.7 +/- 29.2 mug/L]. There was a moderate negative correlation between C(max) and age (Spearman correlation r = -0.42; p = 0.04). The AUC in prepubertal children (91.3 +/- 39.7 mug . h/L) did not differ significantly from the AUC in adolescents (69.3 +/- 57.0 mug . h/L). The t((1/2)) was the same for the two groups: 2.5 +/- 1.1h. Clearance values (CL/f) varied widely between the two groups (group A: 4.3 +/- 1.8 L/min; group B: 11.0 +/- 11.9 L/min; p = 0.08). A moderate positive correlation was found between clearance and age (Spearman correlation r = 0.36; p = 0.09). A large variation was found in the volumes of distribution within the two groups (group A: 31.2 mL/kg [SD 26.7], group B:37.0 mL/kg [SD 29.6]; p = 0.12). A very weak positive correlation was found between age and volume of distribution (Spearman correlation r = 0.11; p = 0.61). A 27% low-density lipoprotein-cholesterol reduction from baseline was achieved at day 14. CONCLUSIONS: Body surface area and gender did not influence the pharmacokinetics of pravastatin in children aged 8-16 years. On the basis of our findings there are no reasons to use pravastatin at a dosage according to bodyweight or to use different dosage regimens from those in adults. However, for prepubertal children half the advised starting dose for adults may be sufficient.

DrugBank Data that Cites this Article

Drugs